Floatz logo

OBI 3424

Pancreatic Adenocarcinoma

OBI Pharma, IncSmall moleculePhase 1/2Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

190 Active assets in the Pancreatic Adenocarcinoma cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 4BBB
Docetaxel
Bristol-Myers Squibb
Phase 2BBB
Irinotecan
Jonsson Comprehensive Cancer Center
Phase 3BB
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
Irinotecan
Ipsen
Phase 3BB

View all 50 →

Same molecule, other indications

OBI 3424 is also rated in:

hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →
T-cell acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
refractory precursor T-lymphoblastic lymphoma/leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →